Dr Nada Lallous

Dr. Nada Lallous has a strong knowledge in protein handling and characterization and wide expertise in preclinical validation of novel inhibitors against various cancer targets, acquired during her PhD in structural biochemistry and biophysics and subsequent >10 years of international cancer research experience. She has led projects from inception to structural determination using X-ray crystallography, and contributed to 20 structures currently available in the Protein Data Bank.

Dr. Lallous joined the Vancouver Prostate Centre as a post-doctoral fellow in 2012. She was mainly involved in elucidating the function of the Binding Function-3 site (BF3) of the androgen receptor (AR) and showed that inhibitors targeting this co-regulator binding pocket could help in overcoming resistance associated with the traditional treatment of advanced and lethal prostate cancer. She also secured an NIH-SPORE grant from the National Cancer Institute to understand the functionality and drug susceptibility of AR variants identified in patients’ circulating cell free DNA (cfDNA). These resistance-associated AR mutations are critically important for predicting and monitoring the response of patients to therapy and ultimately, for the development of evidence-based precision oncology practices. This latter work has led to five peer-reviewed publications and to successful collaborations with various pharmaceuticals companies.

In 2017, Dr. Lallous was appointed as a Research Scientist at the Vancouver Prostate Centre and an Adjunct Professor, UBC Faculty of Medicine. Currently, Dr. Lallous is the manager of the protein bioengineering and biophysics group at the Vancouver Prostate Centre. She and her team are building a core facility to provide support for scientists in their preclinical drug validation and structural studies.

Click here to visit her LinkedIn profile (opens in new window).